Table 3.
Summary of Adverse Events.
| Event | Related to TCZ therapy | Not related to TCZ therapy* | Total |
|---|---|---|---|
| Infections (total) | 9 | 3 | 12 |
| Urinary tract infection | 3 | 2 | 5 |
| Upper respiratory tract infection | 3 | 1 | 4 |
| Skin infection | 3 | 0 | 3 |
| Hematologic disorders (total) | 10 | 0 | 10 |
| Leucopoenia | 3 | 0 | 3 |
| Neutropoenia | 5 | 0 | 5 |
| Thrombocytopoenia | 2 | 0 | 2 |
| Musculoskeletal disorders | 4 | 4 | 8 |
| Metabolic disorders | 5 | 0 | 5 |
| Hyperlipidaemia | 5 | 0 | 5 |
| Hypersensitivity reactions | 3 | 1 | 4 |
| Lack of efficacy | 3 | 0 | 3 |
| Skin disorders | 2 | 2 | 4 |
| Gastrointestinal disorders | 2 | 2 | 4 |
| Cardiovascular Events (total) | 0 | 1 | 0 |
| Transient ischemic attack | 0 | 1 | 0 |
| Nervous system disorders | 0 | 2 | 2 |
| Tumours | 0 | 1 | 1 |
| Adenocarcinoma of uterus | 0 | 1 | 1 |
| Other | 2 | 2 | 4 |
| Total | 40 | 18 | 58 |
*
Not related to TCZ therapy according to the judgment of the treating rheumatologist.